Report Overview

The US Uterine Fibroid Treatment market size stood at around USD 240.1 million in 2019 and is projected to reach USD xx million by 2028, exhibiting a CAGR of XX% during the forecast period

Uterine fibroids, also known as uterine leiomyomas, are the most common tumors affecting the female reproductive tract. These tumors disrupt the function of uterus and causes anemia, excess bleeding, and pelvic discomfort. There are various treatment options available for the treatment of the condition such as drug therapy and surgical procedure



Market Growth Drivers

High incidence of uterine fibroids among women is expected to propel growth of the U.S. uterine fibroids treatment market over the forecast period. For instance, according to the study, A US population-based study of uterine fibroids diagnosis incidence, trends, and prevalence: 2005 through 2014 published in October 2018, the incidence rates for fibroids diagnoses was 240.3 per 10,000 woman-years in 2014 in the age group 4549 years

Moreover, availability of effective therapies is also expected to aid in growth of the market. For instance, ulipristal acetate (UPA) is effective in reducing the symptoms due to uterine leiomyomata. UPA is approved for short-term use prior to surgery and longer-term use